Phase I Nicotinic Agonist Treatment Trial for Autism
Status:
Terminated
Trial end date:
2016-05-01
Target enrollment:
Participant gender:
Summary
This study plans to learn more about whether a nicotine-like investigational new drug, DMXB-A
[3-(2,4-dimethoxybenzylidene) anabaseine] may have positive effects on mental focus and may
help us to find new types of treatment for autism spectrum disorder. Subjects will come in
for a screening visit and three more drug visits. There will be at least one week between
each drug visit to allow the drug to be eliminated from your system completely. During each
drug visit subjects will receive either a placebo (a capsule that looks like medicine but is
not real), 75 mg of DMXB-A, or 150 mg of DMXB-A. During the drug day vital signs and well
being will be monitored by the study physician. Subjects will complete some paper and pencil
tasks to test memory, attention, speed, and problem solving, some rating scales and
questionnaires, and the study team will record brain wave patterns with an
electroencephalogram (EEG) .